|
Q3 FY2026
As of Sep 27, 2026
|
Q2 FY2026
As of Jun 28, 2026
|
Q1 FY2026
As of Mar 29, 2026
|
Q4 FY2025
As of Dec 28, 2025
|
Q3 FY2025
As of Sep 28, 2025
|
Q2 FY2025
As of Jun 29, 2025
|
Q1 FY2025
As of Mar 30, 2025
|
Q4 FY2024
As of Dec 29, 2024
|
Q3 FY2024
As of Sep 29, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Oct 1, 2023
|
Q2 FY2023
As of Jul 2, 2023
|
Q1 FY2023
As of Apr 2, 2023
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||
| Current assets | |||||||||||||||
| Cash and cash equivalents | |||||||||||||||
| Trade receivables, less allowances for credit losses ($15 and $26 as of September 27, 2026 and December 28, 2025, respectively) | |||||||||||||||
| Inventories | |||||||||||||||
| Prepaid expenses and other receivables | |||||||||||||||
| Other current assets | |||||||||||||||
| Total current assets | |||||||||||||||
| Property, plant, and equipment, net | |||||||||||||||
| Intangible assets, net | |||||||||||||||
| Goodwill | |||||||||||||||
| Deferred taxes on income | |||||||||||||||
| Other assets | |||||||||||||||
| Total Assets | |||||||||||||||
| Liabilities and Stockholders’ Equity | |||||||||||||||
| Current liabilities | |||||||||||||||
| Loans and notes payable | |||||||||||||||
| Accounts payable | |||||||||||||||
| Accrued liabilities | |||||||||||||||
| Accrued rebates, returns, and promotions | |||||||||||||||
| Accrued taxes on income | |||||||||||||||
| Total current liabilities | |||||||||||||||
| Total long-term debt | |||||||||||||||
| Deferred taxes on income | |||||||||||||||
| Employee-related obligations | |||||||||||||||
| Other liabilities | |||||||||||||||
| Total liabilities | |||||||||||||||
| Stockholders’ Equity | |||||||||||||||
| Preferred stock, $0.01 par value, 750,000 shares authorized; no shares issued and outstanding as of September 27, 2026 and December 28, 2025 | |||||||||||||||
| Common stock, $0.01 par value, 12,500,000 shares authorized; 1,941,266 and 1,920,880 shares issued and outstanding as of September 27, 2026, respectively; 1,936,502 and 1,916,115 shares issued and outstanding as of December 28, 2025, respectively | |||||||||||||||
| Additional paid-in capital | |||||||||||||||
| Treasury stock, 20,387 and 20,387 shares at cost as of September 27, 2026 and December 28, 2025, respectively | |||||||||||||||
| Accumulated deficit | |||||||||||||||
| Net investment from Johnson & Johnson | |||||||||||||||
| Accumulated other comprehensive loss | |||||||||||||||
| Total stockholders’ equity | |||||||||||||||
| Total Liabilities and Stockholders’ Equity | |||||||||||||||
| Treasury stock, at cost (in shares) | |||||||||||||||
| Preferred stock, par value (in dollars per share) | |||||||||||||||
| Preferred stock outstanding (in shares) | |||||||||||||||
| Preferred stock issued (in shares) | |||||||||||||||
| Preferred stock authorized (in shares) | |||||||||||||||
| Common stock authorized (in shares) | |||||||||||||||
Loading...